Truvada


Also found in: Dictionary, Wikipedia.

Truvada

(tro͞o-vä′də)
A trademark for a drug consisting of a combination of emtricitabine and a prodrug of tenofovir.
References in periodicals archive ?
Based on the iPrEx results, in January 2011 the Centers for Disease Control and Prevention (CDC) issued interim guidance on Truvada as PrEP among high-risk adult MSM.
Truvada is the first medicine recommended to reduce the risk of HIV infection in the EU.
8] Truvada intervention will empower mostly young women to be in control of their infection status, as HIV prevalence and incidence rates remain disproportionately higher in females than in males.
Truvada is not yet approved by any national regulatory body for use as oral PrEP in adolescents.
Participants were asked to take oral Truvada on a daily basis for at least three months and up to one year if they chose to do so.
The prophylactic approach is highly cost-effective - Truvada costs [euro]400 a month, so less than [euro]4,550 a year.
73 for 30 tablets of Truvada, a preexposure prophylaxis (PrEP).
Gilead Sciences, a United States-based biopharmaceutical company, has received marketing authorisation from the European Commission for its once-daily Truvada (emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) in combination with safer-sex practices to decrease the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, it was reported on Tuesday.
Food and Drug Administration is Truvada, made by Gilead Sciences.
Truvada is a combination of two anti-retroviral drugs already used for HIV treatment (tenofovir and emtricitibine); the new approved use is based on research showing that, taken daily before exposure to HIV, the combination offers protection against infection.
Speaking to a select team of journalists in the trial countries of Uganda, Zimbabwe and South Africa via teleconference on Monday afternoon, the lead researchers announced that none of the three products - tenofovir gel, oral tenofovir and oral Truvada proved to be effective among the women enrolled in the VOICE study.